Press Release August 18, 2020

MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

The Life Sciences team advised MyoKardia, Inc. through its strategic collaboration with LianBio to develop and commercialize mavacamten in China and other Asian territories. Mavacamten is MyoKardia’s lead therapeutic candidate being developed for the treatment of patients with hypertrophic cardiomyopathy (HCM), as well as in a targeted population of patients with heart failure with preserved ejection fraction (HFpEF). The partnership will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow, in keeping with MyoKardia’s development strategy.

MyoKardia will receive an upfront payment of $40 million at closing, with additional committed payments within the first six months. MyoKardia may be eligible to receive regulatory and sales milestone payments of up to $147.5 million, as well as double-digit tiered royalties on the sale of mavacamten in the territories outlined as part of the collaboration. In addition, MyoKardia received an equity position in Lian Cardiovascular, a subsidiary of LianBio.  

MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. 
  
The Goodwin team was led by Richard Hoffman and Wenseng “Wendy” Pan, and consisted of Freddy Yip and Rui Miao, with assistance from Daniel Karelitz, Benjamin Gossels, Richard L. Matheny and Paul Jin

For more details, please read the press release and articles in S&P Global Market Intelligence and Xconomy.